We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
SAS Institute Japan announced March 9 that Sankyo, one of Japan's leading pharmaceuticals,
has adopted SAS Drug Development (SDD), SAS's proprietary solution designed
for the pharmaceutical industry which helps streamline the entire drug development
process.
KV Pharmaceutical Company has concluded an exclusive licensing agreement with
Sigma Pharma Ltda., a division of EMS S/A, to market KV's single-dose prescription
cream treatment for bacterial vaginosis (BV) in Brazil.
The drug development company Arexis AB has entered into a collaboration agreement
with the Danish company CMC Biopharmaceuticals on the production of recombinant
human BSSL for the upcoming cystic fibrosis and preterm infant clinical trials.
Sumitomo announced March 8 that its biotech subsidiary Summit Pharmaceuticals
International (SPI) and RIKEN signed a business partnership agreement on January
27.
A group of 19 US senators and representatives have reportedly signed
a letter criticising the US Trade Representative's position on Israel's patent
laws, currently the subject of fractious argument between ethical drugmakers
and the country's government.
The failure of government attempts to freeze price levels from mid-2000
onwards has prompted the Brazilian authorities gradually to reassess drug pricing
policy.
Ukraine's competition authorities have approved the merger of two
local drug manufacturers, Kyivmedpreparat and Halychpharm, in a move widely
seen as an attempt to bolster the country's small drug production sector.
India's GlaxoSmithKline Pharmaceuticals Ltd.'s board will meet on March 15 to
consider a proposal to buy back shares, the Bombay Stock Exchange said on Monday.